DE60106287D1 - Chemische verbindungen - Google Patents

Chemische verbindungen

Info

Publication number
DE60106287D1
DE60106287D1 DE60106287T DE60106287T DE60106287D1 DE 60106287 D1 DE60106287 D1 DE 60106287D1 DE 60106287 T DE60106287 T DE 60106287T DE 60106287 T DE60106287 T DE 60106287T DE 60106287 D1 DE60106287 D1 DE 60106287D1
Authority
DE
Germany
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60106287T
Other languages
English (en)
Other versions
DE60106287T2 (de
Inventor
Giuseppe Alvaro
Fabio Romano Di
Paolo Maragni
Marsia Tampieri
Maria Elvira Tranquillini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE60106287D1 publication Critical patent/DE60106287D1/de
Application granted granted Critical
Publication of DE60106287T2 publication Critical patent/DE60106287T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60106287T 2000-10-17 2001-10-12 Chemische verbindungen Expired - Lifetime DE60106287T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0025354.2A GB0025354D0 (en) 2000-10-17 2000-10-17 Chemical compounds
GB0025354 2000-10-17
PCT/GB2001/004580 WO2002032867A1 (en) 2000-10-17 2001-10-12 Chemical compounds

Publications (2)

Publication Number Publication Date
DE60106287D1 true DE60106287D1 (de) 2004-11-11
DE60106287T2 DE60106287T2 (de) 2006-02-23

Family

ID=9901397

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60142197T Expired - Lifetime DE60142197D1 (de) 2000-10-17 2001-10-12 Pharmazeutische Zusammensetzung
DE60127002T Expired - Lifetime DE60127002T2 (de) 2000-10-17 2001-10-12 Pharmazeutische zusammensetzung
DE60106287T Expired - Lifetime DE60106287T2 (de) 2000-10-17 2001-10-12 Chemische verbindungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60142197T Expired - Lifetime DE60142197D1 (de) 2000-10-17 2001-10-12 Pharmazeutische Zusammensetzung
DE60127002T Expired - Lifetime DE60127002T2 (de) 2000-10-17 2001-10-12 Pharmazeutische zusammensetzung

Country Status (29)

Country Link
US (5) US7119092B2 (de)
EP (4) EP1752449A1 (de)
JP (1) JP3940359B2 (de)
KR (1) KR100847414B1 (de)
CN (1) CN1231468C (de)
AR (1) AR034268A1 (de)
AT (3) ATE278669T1 (de)
AU (4) AU2001295723B2 (de)
BR (1) BR0114637A (de)
CA (1) CA2425876C (de)
CY (1) CY1107634T1 (de)
CZ (1) CZ299824B6 (de)
DE (3) DE60142197D1 (de)
DK (2) DK1326832T3 (de)
ES (3) ES2282794T3 (de)
GB (1) GB0025354D0 (de)
HK (2) HK1058788A1 (de)
HU (1) HU228146B1 (de)
IL (3) IL155165A0 (de)
MX (1) MXPA03003536A (de)
MY (1) MY124957A (de)
NO (1) NO324468B1 (de)
NZ (1) NZ525091A (de)
PL (1) PL203071B1 (de)
PT (2) PT1524266E (de)
SI (2) SI1326832T1 (de)
TW (1) TWI299730B (de)
WO (1) WO2002032867A1 (de)
ZA (1) ZA200302801B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
ATE400568T1 (de) * 2002-12-23 2008-07-15 Janssen Pharmaceutica Nv Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
ATE354572T1 (de) * 2002-12-23 2007-03-15 Janssen Pharmaceutica Nv Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten
WO2004067093A2 (en) * 2003-01-27 2004-08-12 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
FR2853648B1 (fr) * 2003-04-11 2006-08-18 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004087685A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
WO2004089901A2 (en) * 2003-03-31 2004-10-21 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
WO2004110451A1 (en) * 2003-06-10 2004-12-23 Janssen Pharmaceutica N.V. Combinations for opioid-based treatment of pain comprising 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
BRPI0410630A (pt) * 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
GB0514707D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514704D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514705D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
EP2817312B1 (de) 2012-02-22 2016-02-17 Leo Pharma A/S Neuartige neurokinin-1 rezeptorantagonistenverbindungen
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
MA51658A (fr) 2017-04-10 2020-12-02 Chase Therapeutics Corp Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies
EP3645120A4 (de) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation Nk-1 -antagonist-zusammensetzungen und verfahren zur verwendung in der behandlung von depression
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536020A (en) * 1894-04-09 1895-03-19 Washing or bathing apparatus
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0545478A1 (de) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclische Verbindungen als Tachykininantagoniste
US5334387A (en) * 1993-02-23 1994-08-02 Colgate-Palmolive Company Topical composition comprising mono and dialkyl phosphates with a cosurfactant
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
DE59308873D1 (de) 1993-11-26 1998-09-17 Rockwool Mineralwolle Verfahren zum Herstellen einer Schmelze für die Mineralfaserherstellung
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
EP0721941A4 (de) 1994-07-15 1996-09-25 Meiji Seika Co Neue verbindungen mit aggregations-hemmenden wirkung auf bluttplättchen
WO1996003378A1 (fr) 1994-07-26 1996-02-08 Sankyo Company, Limited Derives d'amide n-phenyle et d'uree
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
CA2198382A1 (en) 1994-09-30 1996-04-11 Novartis Ag 1-acyl-4-aliphatylaminopiperidine compounds
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
EE9700141A (et) 1994-12-23 1997-12-15 Dr. Karl Thomae Gmbh Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036592A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507582A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルプロテイントランスフェラーゼの阻害剤
CA2249604A1 (en) 1996-04-03 1997-10-09 Theresa M. Williams Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
WO1998024443A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
AU741725B2 (en) 1997-08-27 2001-12-06 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2309341A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Substituted .beta.-alanine derivatives as cell adhesion inhibitors
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6253732B1 (en) * 1999-11-11 2001-07-03 Ford Global Technologies, Inc. Electronic throttle return mechanism with a two-spring and two-lever default mechanism
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
DE60127002T2 (de) 2007-10-31
AU2009201407A1 (en) 2009-05-07
MXPA03003536A (es) 2003-08-07
ATE468324T1 (de) 2010-06-15
PT1524266E (pt) 2007-05-31
DK1524266T3 (da) 2007-06-25
AU2005204234A1 (en) 2005-09-15
AU2005204234B2 (en) 2009-05-07
CA2425876A1 (en) 2002-04-25
KR100847414B1 (ko) 2008-07-18
DK1326832T3 (da) 2005-01-31
US20040014770A1 (en) 2004-01-22
CN1483025A (zh) 2004-03-17
NO324468B1 (no) 2007-10-22
HU228146B1 (en) 2012-12-28
AU9572301A (en) 2002-04-29
PT1326832E (pt) 2005-01-31
US20060142302A1 (en) 2006-06-29
DE60142197D1 (de) 2010-07-01
IL155165A (en) 2008-11-26
ES2346108T3 (es) 2010-10-08
WO2002032867A1 (en) 2002-04-25
EP1326832B1 (de) 2004-10-06
PL361180A1 (en) 2004-09-20
KR20030036932A (ko) 2003-05-09
US7648990B2 (en) 2010-01-19
NZ525091A (en) 2005-04-29
HK1075889A1 (en) 2005-12-30
HUP0301459A2 (en) 2006-09-28
CZ299824B6 (cs) 2008-12-03
DE60106287T2 (de) 2006-02-23
CZ20031082A3 (cs) 2004-08-18
JP2004511544A (ja) 2004-04-15
GB0025354D0 (en) 2000-11-29
HK1058788A1 (en) 2004-06-04
EP1921064A1 (de) 2008-05-14
EP1921064B1 (de) 2010-05-19
EP1752449A1 (de) 2007-02-14
ATE278669T1 (de) 2004-10-15
NO20031561L (no) 2003-06-14
IL155165A0 (en) 2003-10-31
AU2001295723B2 (en) 2005-05-26
CY1107634T1 (el) 2013-04-18
EP1524266B1 (de) 2007-02-28
CN1231468C (zh) 2005-12-14
AU2009201407B2 (en) 2011-12-15
ES2282794T3 (es) 2007-10-16
US7119092B2 (en) 2006-10-10
ZA200302801B (en) 2004-04-21
US7060702B2 (en) 2006-06-13
HUP0301459A3 (en) 2007-11-28
SI1326832T1 (en) 2005-02-28
AR034268A1 (es) 2004-02-18
ATE355271T1 (de) 2006-03-15
CA2425876C (en) 2009-07-07
US20050137208A1 (en) 2005-06-23
US20100081667A1 (en) 2010-04-01
PL203071B1 (pl) 2009-08-31
IL191486A0 (en) 2008-11-03
DE60127002D1 (de) 2007-04-12
NO20031561D0 (no) 2003-04-07
BR0114637A (pt) 2003-09-30
MY124957A (en) 2006-07-31
EP1524266A1 (de) 2005-04-20
US7294630B2 (en) 2007-11-13
EP1326832A1 (de) 2003-07-16
JP3940359B2 (ja) 2007-07-04
TWI299730B (en) 2008-08-11
US20080021041A1 (en) 2008-01-24
ES2227287T3 (es) 2005-04-01
SI1524266T1 (sl) 2007-08-31

Similar Documents

Publication Publication Date Title
DE60106287D1 (de) Chemische verbindungen
DE60210782D1 (de) Glukokinase beeinflussende verbindungen
AR028414A1 (es) Compuestos quimicos
ATE299875T1 (de) Benzoamid-piperidin verbindungen als substanz p- antagonisten
AR028605A1 (es) Compuesto quimico
NO20021637L (no) Kjemikalske forbindelser
ATE298748T1 (de) (1,4')-bipiperidin verbindungen
DE60031481D1 (de) Polymer-gebundene funktionelle Verbindungen
DE60206605D1 (de) Chemische verbindungen
ATE384726T1 (de) Bicyclische heteroaromatische verbindungen
DE60131781D1 (de) Kalzilytische verbindungen
DE60137755D1 (de) Calcilytische verbindungen
DE60228478D1 (de) Aryl-annellierte azapolyzyklische verbindungen
SE0004925L (sv) Kemiska föreningar
SE0003664D0 (sv) Chemical compounds
AR028304A1 (es) Compuestos quimicos
DE60200804D1 (de) Halogen-enthaltende aromatische Verbindungen
SE0103797D0 (sv) Chemical compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition